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ABSTRACT
Background. Given the role of microRNA in colorectal
cancer (CRC) progression, we explored the association
between microRNA (miRNA) expression and CRC-related
prognosis.
Methods. Three types of tissue samples (primary CRC
lesions without liver metastasis, primary lesions with liver
metastasis, and liver metastatic tissues) were used for
miRNA profiling to identify differentially expressed
miRNA. Quantitative real-time PCR was used to examine
miRNA expression in CRC cells and in tumor tissues.
Results. MiR-132 was significantly down-regulated in
primary CRC tissues with liver metastasis and liver meta-
static lesions compared to primary lesions without liver
metastasis. Multivariate analysis for overall survival indi-
cated that low miR-132 expression was an independent
prognostic factor for CRC patients (overall survival
P = 0.040, disease-free survival P = 0.015). Ectopic
expression of miR-132 significantly inhibited cell prolif-
eration and cell invasion. The luciferase reporter assay
revealed that anoctamin 1 (ANO1) was a direct target of
miR-132. Kaplan–Meier survival curves showed that high
ANO1 expression was a significant prognostic factor for
overall survival of patients with CRC (P = 0.0344).
Conclusions. Down-regulation of miR-132 is associated
with poor prognosis in CRC. ANO1 could be one of the
crucial targets of miR-132 in CRC.
Colorectal cancer (CRC) is one of the most prevalent
carcinomas throughout the world.1 The liver is the most
common organ for distant CRC metastasis, and liver
metastasis is the leading cause of cancer-related death in
CRC patients.2 Approximately 30–50 % of CRC patients
develop local tumor recurrence or distant metastasis after
curative resection of the primary lesion.3,4 New diagnostic
markers that can detect early metastasis or predict the risk
of metastasis in CRC are in urgent demand.5
Micro RNAs (miRNAs) are small, noncoding RNA
molecules of *19–25 nucleotides that potentially regulate
20–30 % of gene expression.6 Each miRNA has numerous
targets, and depending on its target genes, a miRNA can
play significant roles in tumor metastasis.7 In recent years,
over 100 miRNAs have been implicated in CRC.8 How-
ever, more influential research is required to reveal how
miRNAs act within the context of the molecular mecha-
nisms for disease recurrence of CRC.
In this study, we conducted a microarray-based analysis
to recognize differentially expressed miRNAs in CRC by
comparing miRNA profiles among primary CRC tissues
from patients without liver metastasis, primary tissues with
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liver metastasis, and liver metastatic lesions. After the
miRNA array analysis, we evaluated the role of miR-132 in
human CRC.
MATERIALS AND METHODS
Collection of Human Tissue Specimens
The testing cohort consisted of 28 primary CRC lesions
and eight metastatic liver tumors that arose from CRC.
Sixteen primary CRC lesion samples were collected from
patients with stage II and III disease without liver metastasis
during the follow-up period (median 1898 days, range 27–
2155 days) after operation. Twelve primary CRC lesion
samples were from patients with concomitant liver metas-
tasis. The extended independent validation cohort consisted
of tissue samples from 151 patients [135 primary lesions
(109 without liver metastasis and 26 with liver metastasis),
and 16 liver metastatic lesions arising from CRC]. These 135
patients included patients with stage I (n = 30), stage II
(n = 42), and stage III (n = 37) CRC. The median follow-
up period for these 135 patients was 1653 days (range 27–
2228 days). The clinical characteristics of the testing cohort
and the validation cohort are summarized in Supplementary
Table S1. To compare the expression of miRNA in tumor
versus normal tissues, the primary CRC tissues (n = 21) and
their adjacent normal tissues (n = 21) were assessed using
quantitative real-time PCR (qRT-PCR). All patients were
resected with curative intent between 2003 and 2013 at
Osaka University Hospital and its three related hospitals. The
samples were stored at -80 C as a fresh frozen samples
with RNAlater (Ambion, Austin, TX, USA) until RNA
extraction. All patients provided written informed consent,
in accordance with the guidelines approved by the institu-
tional research board of each institute.
RNA Extraction
Total RNA from tissues and cells were isolated using the
miRNeasy Mini Kit (Qiagen, Hilden, Germany) and Trizol
reagent (Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s protocol.
Microarray Analysis
Microarray analysis (Sureprint G3 Humans miRNA
8 9 60 K; Agilent Technologies, Santa Clara, CA, USA)
was performed for the testing cohort (n = 36) at Hokkaido
System Science Corporation (Hokkaido, Japan) using
miRNA Complete Labeling Reagent and Hyb Kit (Agilent
Technologies). The microarray raw data are available in
Gene Expression Omnibus (GEO; https://www.ncbi.nlm.
nih.gov/geo/) database with accession code GSE72199.
Reverse Transcription PCR and TaqMan miRNA Assay
In the TaqMan microRNA Assay (Applied Biosystems,
Foster City, CA, USA), hsa-miR-132 ID 000457 and
RNU6B ID 001093 were used to measure miRNA levels.
The TaqMan MicroRNA Reverse Transcription kit and
TaqMan 29 universal PCR Master Mix, No AmpErase
UNG (Applied Biosystems), were used according to the
manufacturer’s protocol. The 7900HT Sequence Detection
System 2.3 (Applied Biosystems) software was used to
compute the relative change in RNA expression by the
2DDCt method.
qRT-PCR
Total RNA was reverse transcribed using the High
Capacity RNA-to-cDNA Kit (Applied Biosystems). We
performed qRT-PCR using the TaqMan Gene Expression
Assay (Applied Biosystems) following the manufacturer’s
protocol.
Cell Lines and Cell Culture
All human CRC cell lines (DLD-1 and HCT116) were
obtained from the American Type Culture Collection in
2001. Cell lines were cultured in Dulbecco’s modified
Eagle medium (DMEM D6046; Sigma Aldrich, St. Louis,
MO, USA) containing 10 % fetal bovine serum in a
humidified incubator under 5 % CO2 at 37 C.
Cell Transfection
To perform transient transfections, the cells were
transfected using Lipofectamine RNAiMAX (Invitrogen),
with 25 nmol/L of miRVana miRNA mimic miR-132–3p
(#4464066) and miRVana miRNA inhibitor miR-132–3p
(#4464064), according to the manufacturer’s instructions.
The control miRNAs [Negative Control #1 mimic
(#4464058) and Negative Control #1 (#4464074)] were
used as a control for nonspecific effects.
Proliferation Assays
Cells were seeded at a density of 2.5–3 9 104 per well
in 24-well dishes and cultured for 72 h to determine pro-
liferation. Cells were counted with a Celltac automatic
hematology analyzer (Nihon Kohden, Tokyo, Japan).
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Colony Formation
For colony formation assays, 500 transfected cells were
plated in six-well plates. After incubation at 37 C for
11 days, visible colonies were fixed with formalin and
stained with Giemsa solution, and the numbers of colonies
were counted using a microscope in 10 random visual
fields (94 magnification, n = 4).
Invasion Assay
The cell invasion assay was performed using transwell
inserts with 8 lm pores (BD Biosciences, San Jose, CA,
USA), in accordance with the manufacturer’s protocol. The
invading cells were counted using a microscope in three
random visual fields (9200 magnification).
Luciferase Reporter Assay
We amplified the ANO1 30 untranslated region (30 UTR)
containing the putative miR-132 binding sites by PCR
using following primers: ANO1 (forward) 50-
GCTCGCTAGCCTCGAGGGGGCGTGGGAGCATCC-
30, (reverse) 50-ATGCCTGCAGGTCGATGGCA-
GATTAAAGGGAATGT-30. The resulting DNA fragment
was inserted at restriction sites immediately downstream of
the luciferase gene in the pmirGLO vector (Promega,
Madison, WI, USA). Luciferase activity was measured
using the Dual Luciferase Reporter Assay System (Pro-
mega). Firefly luciferase activity was normalized against
Renilla luciferase activity for each transfected well.
Statistical Analysis
Data were expressed as means ± standard deviations.
Statistical analysis was performed using JMP Pro 10 software
(SAS Institute, Cary, NC, USA). Statistical significance was
compared using the Chi square test, and continuous variables
were compared using Student’s t test or one-way analysis of
variance, as appropriate. Survival curves were generated using
the Kaplan–Meier method and assessed using the log-rank
test. The Cox proportional hazard regression model was per-
formed to identify independent prognostic factors. A value of
P\ 0.05 was considered statistically significant.
RESULTS
Expression of miR-132 in Colorectal and Hepatic
Tissue Samples
To explore the possible role of miRNA in CRC, miRNA
expression was profiled in the testing cohort, which con-
sisted of primary CRC tumor tissue from patients without
liver metastasis (n = 16), tumor tissue from patients with
liver metastasis (n = 12), and liver metastatic lesions
(n = 8). MiRNA array analysis identified 39 miRNAs
(Supplementary Table S2) whose expression levels differed
between primary CRC lesions without and with liver
metastasis ([2-fold change). Among them, we found that a
tumor suppressor miR-132 expression was significantly
lower in CRC liver metastatic lesions than in primary CRC
lesions without liver metastasis (Fig. 1a).9 The microarray
results of miR-132 expression were validated by qRT-PCR
in the same testing cohort of 36 CRC tissues. The
expression of miR-132 was significantly higher in primary
CRC lesions without and with liver metastasis than in liver
metastatic lesions (Supplementary Fig. S1a). A statistically
significant correlation was observed between microarray
data and qRT-PCR miR-132 expression data (r = 0.549,
P = 0.0005; Supplementary Fig. S1b).
On the basis of the preliminary data, we then examined
miR-132 expression by qRT-PCR in the independent and
extended validation cohort of 151 patients (109 primary
CRC lesions without liver metastasis, 26 primary lesions
with liver metastasis, and 16 liver metastatic lesions). As
results, miR-132 expression was significantly down-regu-
lated in primary CRC lesions with liver metastasis and in
liver metastatic lesions compared to primary CRC lesions
without liver metastasis (Fig. 1b, P = 0.0019 and
P = 0.0002, respectively). In this study, we analyzed seven
pairs of primary CRC and corresponding synchronous liver
metastases that were collected from both microarray and
validation cohort. MiR-132 expression was significantly
down-regulated in corresponding liver metastases com-
pared to primary CRC lesions (Fig. 1c, P = 0.0462). When
we measured the difference expression between tumor and
normal tissues, miR-132 expression was significantly
increased in tumor tissues (n = 21) compared to their pair-
matched adjacent normal colonic tissues (Fig. 1d,
P = 0.0268).
Overexpression of miR-132 Suppresses CRC Cell
Growth and Invasion In Vitro
CRC cells were transfected with miR-132 mimics, and
the transfection efficiency was measured through real-time
PCR. There was significantly higher miR-132 expression in
miR-132-transfected cells at every time point compared to
negative control (NC) miR-transfected cells (Supplemen-
tary Fig. S2). MiR-132-transfected CRC cells demonstrated
a significantly slower growth rate than NC (Fig. 2a).
Results of the colony-formation assay indicated that miR-
132 overexpression significantly inhibited tumor growth
(Fig. 2b). Because cell invasion is an initial step of
metastasis, we examined the effect of miR-132 on the
invasive capacity of CRC cell lines. MiR-132
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overexpression markedly reduced the invasion ability
compared to NC (Fig. 2c). In contrast, inhibiting miR-132
expression (inhibitor miR-132) showed increased invasion
ability compared to NC (Fig. 2c).
MiR-132 Directly Targets 30 UTR of ANO1 in CRC
Cells
To reveal the biological potential role of miR-132 in
CRC, we explored the targets of miR-132. Using 390
expression arrays of CRC in the GEO database
(GSE41258) and the target prediction tool TargetScan 6.2,
we predicted the potential target genes. We identified 54
genes (Supplementary Table S3) and focused ANO1 as a
potential target of miR-132. MiR-132 overexpression
markedly suppressed ANO1 mRNA expression levels
(Fig. 3a), while miR-132 inhibitor resulted in the up-reg-
ulation of ANO1 mRNA expression levels (Fig. 3b). The 30
UTR of ANO1 mRNA contains a complementary site for
the seed region of miR-132 (Fig. 3c). More specifically, in
order to show that ANO1 is a direct target of miR-132, we
















































































































































FIG. 1 Expression of miR-132 in colorectal and hepatic tissue
samples. a Microarray data showed that miR-132 expression was
significantly lower in liver metastatic lesions than in primary CRC
tumors from patients without liver metastasis. b In extended
validation cohort, qRT-PCR showed that miR-132 expression was
significantly down-regulated in primary CRC lesions with liver
metastasis and in liver metastatic lesions compared to primary CRC
lesions without liver metastasis. c MiR-132 expression of seven pairs
of primary CRC was significantly down-regulated in corresponding
synchronous liver metastases. d MiR-132 expression was significantly
increased in tumor tissues (n = 21) compared to their pair-matched
adjacent normal colon tissues (P = 0.0268)
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ANO1 30 UTR sequence containing luciferase reporter
constructs. The activity of a luciferase reporter containing
the predicted miR-132 binding sequence of ANO1 30 UTR
was significantly repressed by the ectopic expression of
miR-132 (Fig. 3d).
Up-regulation of ANO1 Is Inversely Associated with
Down-regulation of miR-132 in CRC Clinical Samples
The above results prompted us to investigate whether
miR-132 suppresses CRC growth and metastasis through
ANO1 suppression. To further confirm the clinical
relationship between miR-132 and ANO1 in CRC patients,
we utilized qRT-PCR to examine ANO1 expression in the
same validation cohort of 151 tissue samples that were
used to examine miR-132 expression. ANO1 expression
was higher in primary CRC with liver metastasis and in
liver metastases than in primary tumors without metastasis
(P = 0.0059, and P = 0.0001, respectively) (Fig. 3e).
There was no significant difference in expression between
tumors with liver metastasis and liver metastasis. More-
over, we found a significant inverse correlation between
miR-132 expression levels and ANO1 expression levels in






























































































































































FIG. 2 In vitro transduction of miR-132 in CRC cells. a MiR-132-
transfected cells demonstrated significantly slower growth rate than
negative control-transfected cells. b Colony formation assay showed
that miR-132 overexpression resulted in significant inhibition of
tumor growth. c MiR-132 overexpression markedly reduced invasion
ability compared to negative control. In contrast, miR-132 inhibitor
increased invasion ability. Data are presented as mean ± SD. NC
negative control-transfected cells, mimic miR-132 miR-132-trans-
fected cells, inhibitor miR-132 inhibitor miR-132-transfected cells.
*P\ 0.05





























































































































































































































































FIG. 3 ANO1 as possible target of miR-132. a MiR-132 expression
markedly suppressed ANO1 mRNA levels. b MiR-132 inhibitor
resulted in up-regulation of ANO1 mRNA levels. c The 30 UTR of
ANO1 mRNA contains site for seed region of miR-132. d Activity of
luciferase reporter containing predicted miR-132 binding sequence of
ANO1 30 UTR was significantly repressed by ectopic expression of
miR-132. e ANO1 expression was higher in primary CRC with liver
metastasis and in liver metastases than in primary tumors without
metastasis (P = 0.0059 and P = 0.0001, respectively). f Significant
inverse correlation was observed between miR-132 expression and
ANO1 expression in validation cohort. Data are presented as
mean ± SD. NC negative control-transfected cells, mimic miR-132
miR-132-transfected cells, inhibitor miR-132 inhibitor miR-132-
transfected cells. *P\ 0.05
S604 Y. Mokutani et al.
MiR-132 Acts as Prognostic Marker of CRC
The clinicopathologic implications of miR-132 expres-
sion were assessed in 135 CRC patients from the validation
cohort of primary CRC tissue samples. To clarify the
correlation of miR-132 expression and postoperative sur-
vival of patients, we divided the patients into two groups
according to the median value (1.299) of the miR-132
TABLE 1 Univariate and multivariate analyses for overall survival
Characteristic Univariate analysis P Multivariate analysis P
RR 95 % CI RR 95 % CI
Sex
Male/female 0.586 0.215–1.593 0.288
Lesion
Colon/rectum 0.783 0.288–2.129 0.626
Differentiation
tub1, tub2/muc, por 0.302 0.084–1.933 0.173
Tumor size
B35 mm/[35 mm 0.566 0.130–1.756 0.347
Depth
T1, T2/T3, T4 \0.0001 0.386–0.386 0.003* \0.0001 \0.0001–2.574 0.192
Lymph node metastasis
Negative/positive 0.156 0.036–0.483 0.001* 1.852 0.409–6.243 0.383
Lymphatic permeation
Negative/positive 0.064 0.004–0.315 \0.0001* 0.103 0.006–0.537 0.004*
Venous permeation
Negative/positive 0.277 0.064–0.861 0.025* 0.890 0.196–2.999 0.860
Stage
I, II/III, IV \0.0001 0.0968–0.0968 \0.0001* \0.0001 \0.0001–0.218 0.002*
miR-132 expression
Low/high 7.255 2.026–46.207 0.001* 3.838 1.054–24.683 0.040*
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FIG. 4 MiR-132 acts as
prognostic marker for CRC. a
Kaplan–Meier survival curves
showed that patients with low
miR-132 expression
demonstrated poorer clinical
outcome (OS, P = 0.0021,
median follow-up 1653 days). b
Patients with low ANO1 levels
had more favorable clinical
outcome (OS) than patients with
high ANO1 levels. c DFS rate
were significantly lower in
patients with low miR-132
expression than in patients with
high miR-132 expression
(P = 0.0220)
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expression. Low miR-132 expression was positively asso-
ciated with tumor size, depth, lymph node metastasis,
venous permeation, and clinical disease stage (Supple-
mentary Table S4). Kaplan–Meier survival curves showed
that patients with low miR-132 expression demonstrated
significantly worse clinical outcome [overall survival (OS):
log-rank test P = 0.0021; median follow-up: 1653 days;
Fig. 4a]. Univariate analysis for OS revealed that tumor
depth, lymph node metastasis, lymphatic permeation,
venous permeation, clinical stage, and miR-132 expression
were significantly associated with OS (Table 1). Multi-
variate analysis for OS indicated that miR-132 expression
(relative risk 3.838, 95 % confidence interval 1.054–
24.683, P = 0.040), lymphatic permeation, and clinical
stage were independent prognostic factors for CRC patients
(Table 2).
To examine the association of ANO1 expression with
clinical outcome, we divided the patients into two groups
according to the median value (0.0055) of the ANO1
expression. Kaplan–Meier survival curves revealed that
patients with low ANO1 expression had a more favorable
clinical outcome (OS) than patients with high ANO1
expression (log-rank test P = 0.0344, Fig. 4b). These
results suggest that ANO1 up-regulation through miR-132
suppression might affect the clinical outcome (OS) of
patients with CRC.
In 109 samples from patients with CRC (excluding 26
stage IV CRCs with liver metastasis), disease-free survival
(DFS) rate were significantly lower in patients with low
miR-132 expression than in patients with high miR-132
expression (log-rank test P = 0.0220, Fig. 4c). Low miR-
132 expression was positively associated with large tumor
size and deep invasion (Supplementary Table S5). In
addition, univariate and multivariate analysis showed that
miR-132 expression was an independent risk factor for
DFS (P = 0.015; median follow-up: 1659 days; Table 2)
in CRC patients. On the other hand, ANO1 expression was
not a significant parameter for DFS (data not shown).
DISCUSSION
Recent miRNA studies have highlighted cancer invasion
and metastasis. Following microarray study, miR-214 and
miR-181a were already suggested as regulators of CRC
liver metastasis.10,11 In the present study, we examined
miRNA profiles in primary CRC lesions with and without
liver metastasis and in liver metastatic lesions to identify
the key miRNA related to CRC.
On the basis of the microarray data, we validated the
miR-132 expression in a larger independent validation
cohort. MiR-132 was definitely down-regulated in primary
CRC lesions with liver metastasis and also in liver
TABLE 2 Univariate and multivariate analyses for disease-free survival
Characteristic Univariate analysis Multivariate analysis
RR 95 % CI P RR 95 % CI P
Sex
Male/female 0.978 0.295–3.733 0.972
Lesion
Colon/rectum 0.697 0.201–2.314 0.550
Differentiation
tub1, tub2/muc, por 0.148 0.038–0.971 0.047* 0.099 0.016–0.765 0.030*
Tumor size
B35 mm/[35 mm 0.235 0.013–1.227 0.094
Depth
T1, T2/T3, T4 \0.0001 0.429–0.429 0.005* \0.0001 0.269–1.201 0.071
Lymph node metastasis
Negative/positive 0.179 0.039–0.620 0.006* 0.331 0.071–1.183 0.090
Lymphatic permeation
Negative/positive 0.286 0.063–0.990 0.048* 0.277 0.060–0.978 0.046*
Venous permeation
Negative/positive 0.767 0.221–2.547 0.661
miR-132 expression
Low/high 5.01 1.290–32.834 0.018* 5.838 1.374–42.770 0.015*
RR relative risk, CI confidence interval
* Statistically significant
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metastatic lesions. Furthermore, down-regulation of miR-
132 was associated with poorer OS and DFS in patients
with CRC.
MiR-132 has been reported as a tumor suppressor in a
series of cancers.9,12–15 Zheng et al. showed that miR-132
inhibits CRC invasion and metastasis via directly targeting
ZEB2 using 62 CRC samples.15 Our study extended their
findings with a possible target ANO1 using a large scale of
CRC samples (n = 163) as well as their metastatic lesions
to liver (n = 24). Of interest was that low miR-132
expression was still maintained in hepatic metastatic
lesions (Fig. 1b). Moreover, direct comparison of seven
paired samples between primary CRC tumor and its cor-
responding synchronous hepatic metastases showed that
hepatic metastases had even smaller amount of miR-132
compared to primary CRC tumors (Fig. 1c), although the
paired number was limited in this study. From a therapeutic
point of view, therefore, it is worth exploring whether
mimic miR-132 would inhibit liver metastasis in animal
models. Further study would clarify more about the close
link of miR-132 with liver metastasis.
When we compared miR-132 levels between normal and
tumor tissues, we found that miR-132 expression was even
higher in tumor tissues than in normal tissues. This result
appears to be paradoxical to our finding of down-regulation
of miR-132 in advanced or metastatic stage tumors. In this
regard, Kara et al. showed a supportive result that miR-132
in CRC tissues had approximately threefold increase of that
in normal mucosa.16 Therefore, we postulate that miR-132
might have differential roles in carcinogenesis and in tumor
progression, although further studies are required to reach a
definitive conclusion.
Each miRNA can potentially down-regulate many target
genes by binding their 30 UTRs. Our results showed that
ANO1 is a target of miR-132 that has a crucial role in CRC
progression. ANO1 is also known as discovered on gas-
trointestinal stromal tumor protein (DOG1) and tumor-
amplified and overexpressed sequence 2 (TMEM16A), and
it is highly deregulated in different human cancers.17–19
These studies showed that ANO1 was a critical oncogenic
factor that contributed to cell motility, invasion, and
adhesion. Furthermore, the overexpression of ANO1 has a
significant effect on both distant metastasis and poor
prognosis. Our results suggest a potential role for ANO1 in
CRC through miR-132. ANO1, which consists of 26 exons
and encodes a protein that contains eight transmembrane
regions, acts as a calcium-activated chloride channel.20–22
Calcium-activated chloride channels have recently become
notable as a new drug target for anticancer therapy.23
ANO1 may contribute to this potential new approach to
cancer therapy.
In conclusion, we demonstrated that lower expression of
miR-132 in clinical CRC specimens was associated with
CRC progression and poor survival. The tumor-suppressing
function of miR-132 may in part be realized through tar-
geting of the downstream gene ANO1. Our data suggest
that further study is essentially important to reveal the
relation between miR-132 and liver metastasis as well as
the potential of miR-132 as a therapeutic target of CRC.
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